NGNoah Gorelick

Noah Gorelick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noah Gorelick has a total of 127 co-authors. Here are the top co-authors by number of shared publications:

  • Betty Tyler

    Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA

    8 shared publications
  • Henry Brem

    Department of Neurosurgery, Johns Hopkins University School of Medicine; Department of Biomedical Engineering, Johns Hopkins University School of Medicine; Department of Ophthalmology, Johns Hopkins University School of Medicine; Department of Oncology, Johns Hopkins University School of Medicine

    8 shared publications
  • Nicolas Skuli

    Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland

    5 shared publications
  • Riccardo Serra

    Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    5 shared publications
  • Joshua Casaos

    Johns Hopkins University

    4 shared publications
  • Betty Tyler

    Department of Neurosurgery, Johns Hopkins University School of Medicine

    3 shared publications

Latest Publications

  • Open Access

    Translational Regulation by hnRNP H/F Is Essential for the Proliferation and Survival of Glioblastoma

    by Morgane Le Bras, Noah Gorelick, Sylvain Pautet, Betty Tyler, Stéphane Manenti, Nicolas Skuli, Stefania Millevoi, Anne Cammas

    Deregulation of mRNA translation is a widespread characteristic of glioblastoma (GBM), aggressive malignant brain tumors that are resistant to conventional therapies. RNA-binding proteins (RBPs) play a critical role in translational regulation, yet the mechanisms and impact of these regulations on cancer development, progression and response to therapy remain to be fully understood. Here, we showed that hnRNP H/F RBPs are potent regulators of translation through several mechanisms that converge to modulate the expression and/or the activity of translation initiation factors. Among these, hnRNP H/F regulate the phosphorylation of eIF4E and its translational targets by controlling RNA splicing of the A-Raf kinase mRNA, which in turn modulates the MEK-ERK/MAPK signaling pathway. The underlying mechanism involves RNA G-quadruplex (RG4s), RNA structures whose modulation phenocopies hnRNP H/F translation regulation in GBM cells. Our results highlighted that hnRNP H/F are essential for key functional pathways regulating proliferation and survival of GBM, highlighting its targeting as a promising strategy for improving therapeutic outcomes.


  • Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies

    by John Choi, Yuan Rui, Jayoung Kim, Noah Gorelick, David R. Wilson, Kristen Kozielski, Antonella Mangraviti, Eric Sankey, Henry Brem, Betty Tyler, et al.


  • Open Access

    Multi-layered core-sheath fiber membranes for controlled drug release in the local treatment of brain tumor

    by Daewoo Han, Riccardo Serra, Noah Gorelick, Umailla Fatima, Charles G. Eberhart, Henry Brem, Betty Tyler, Andrew J. Steckl

    Interstitial chemotherapy plays a pivotal role in the treatment of glioblastoma multiforme (GBM), an aggressive form of primary brain cancer, by enhancing drug biodistribution to the tumor and avoiding systemic toxicities. The use of new polymer structures that extend the release of cytotoxic agents may therefore increase survival and prevent recurrence. A novel core-sheath fiber loaded with the drug carmustine (BCNU) was evaluated in an in vivo brain tumor model. Three-dimensional discs were formed from coaxially electrospun fiber membranes and in vitro BCNU release kinetics were measured. In vivo survival was assessed following implantation of discs made of compressed core-sheath fibers (NanoMesh) either concurrently with or five days after intracranial implantation of 9L gliosarcoma. Co-implantation of NanoMesh and 9L gliosarcoma resulted in statistically significant long-term survival (>150 days). Empty control NanoMesh confirmed the safety of these novel implants. Similarly, Day 5 studies showed significant median, overall, and long-term survival rates, suggesting optimal control of tumor growth, confirmed with histological and immunohistochemical analyses. Local chemotherapy by means of biodegradable NanoMesh implants is a new treatment paradigm for the treatment for brain tumors. Drug delivery with coaxial core-sheath structures benefits from high drug loading, controlled long-term release kinetics, and slow polymer degradation. This represents a promising evolution for the current treatment of GBM.


  • Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste

    by Stuart J. Smith, Betty M. Tyler, Toby Gould, Gareth J. Veal, Noah Gorelick, Jonathan Rowlinson, Riccardo Serra, Alison Ritchie, Phillip Berry, Annette Otto, et al.

    Purpose: High-grade glioma (HGG) treatment is limited by the inability of otherwise potentially efficacious drugs to penetrate the blood–brain barrier. We evaluate the unique intracavity delivery mode and translational potential of a blend of poly(DL-lactic acid-co-glycolic acid; PLGA) and poly(ethylene glycol; PEG) paste combining temozolomide and etoposide to treat surgically resected HGG. Experimental Design: To prolong stability of temozolomide prodrug, combined in vitro drug release was quantitatively assessed from low pH–based PLGA/PEG using advanced analytic methods. In vitro cytotoxicity was measured against a panel of HGG cell lines and patient-derived cultures using metabolic assays. In vivo safety and efficacy was evaluated using orthotopic 9L gliosarcoma allografts, previously utilized preclinically to develop Gliadel. Results: Combined etoposide and temozolomide in vitro release (22 and 7 days, respectively) was achieved from a lactic acid–based PLGA/PEG paste, used to enhance stability of temozolomide prodrug. HGG cells from central-enhanced regions were more sensitive to each compound relative to primary lines derived from the HGG-invasive margin. Both drugs retained cytotoxic capability upon release from PLGA/PEG. In vivo studies revealed a significant overall survival benefit in postsurgery 9L orthotopic gliosarcomas, treated with intracavity delivered PLGA/PEG/temozolomide/etoposide and enhanced with adjuvant radiotherapy. Long-term survivorship was observed in over half the animals with histologic confirmation of disease-free brain. Conclusions: The significant survival benefit of intracavity chemotherapy demonstrates clinical applicability of PLGA/PEG paste-mediated delivery of temozolomide and etoposide adjuvant to radiotherapy. PLGA/PEG paste offers a future platform for combination delivery of molecular targeted compounds.


  • The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?

    by Joshua Casaos, Noah L. Gorelick, Sakibul Huq, John Choi, Yuanxuan Xia, Riccardo Serra, Raphael Felder, Tarik Lott, Richard E. Kast, Ian Suk, et al.

    The growing cost of medical care worldwide, particularly in oncology, has incentivized researchers and physicians to repurpose clinically used drugs to alleviate the financial burden of drug development and offer potential new therapeutics. Recent works have demonstrated anticancer properties of the FDA-approved drug ribavirin, a synthetic guanosine analogue and antiviral molecule used over the past four decades for the treatment of hepatitis C. The efficacy of ribavirin in cancer has been explored through several preclinical models and ongoing clinical trials in multiple cancers, including acute myeloid leukemia, oropharyngeal squamous cell carcinoma, and metastatic breast cancer. In this review, we summarize the role of ribavirin as an antiviral medication and focus our attention on its recent use as an antitumoral agent. We highlight current knowledge of the potential use and mechanisms of action of ribavirin in cancer. Because current therapeutics for patients with cancer still fail to cure, introducing new forms of treatment is essential. Converging evidence suggests that ribavirin represents a promising addition to a generation of newly repurposed safe and effective anticancer agents.


  • Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer

    by Tovi Shapira-Furman, Riccardo Serra, Noah Gorelick, Marisol Doglioli, Valentina Tagliaferri, Arba Cecia, Michael Peters, Awanish Kumar, Yakir Rottenberg, Robert Langer, et al.


  • Open Access

    Solitary sclerosis presenting as isolated spontaneous paroxysmal dysarthria

    by Yuanxuan Xia, Thomas Shoemaker, Noah Gorelick, Justin C. McArthur


  • RARE-01. IN VIVO IMMUNOMODULATING EFFECT OF LXR-623 AND ITS SYNERGISM WITH CHECKPOINT BLOCKADE AGAINST CHORDOMAS IN A HUMANIZED MOUSE MODEL

    by Wataru Ishida, Riccardo Serra, Noah Gorelick, Yuanxuan Xia, Joshua Casaos, Christine Shrock, Alexander Perdomo-Pantoja, Betty Tyler, Sheng-Fu Lo

    We previously developed a humanized mouse model of chordomas, which allowed us to investigate the interaction between human chordomas and human immune cells. This platform is particularly useful for studying immunotherapy against rare cancers such as chordomas, where murine equivalents are currently unavailable. We aim to utilize this model to study synergism between PD-1 blockade and LXR-623, a synthetic agonist of liverX receptors, a class of anti-neoplastic agents disrupting cancer cholesterol-metabolism. Our preliminary data suggest that LXR-623 downregulates PD-L1 on chordoma cell lines and reduces immunosuppressive myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. To achieve immune system reconstitution/humanization, 20 NSG-SGM3 mice were engrafted with human fetal thymus and CD34+ stem cells, whose HLA-types were partially-matched with those of the U-CH1 chordoma cell lines. They were divided into the following groups (n=5 for each group): control group (isotype antibodies (Abs) + vehicle), LXR-623 monotherapy group (isotype Abs + LXR-623 100mg/kg, i.p., daily for 4 weeks), anti-PD-1 Abs monotherapy group (anti-human-PD-1-Abs (Clone: J116), 10 mg/kg, i.p., 3 times/week for 4 weeks), and combination group (anti-human-PD-1 Abs + LXR-623). Anti-tumor activities will be monitored via tumor size measurement, flow cytometric analyses of peripheral blood and spleen as well as chordomas, using various Abs including anti-mouse-CD45, anti-human-CD3, anti-human-CD4, anti-human-CD8, anti-human-CD11b, anti-human-CD14, anti-human-CD15, anti-human-CD19, anti-human-CD25, anti-human-CD45, anti-human-CD45RA, anti-human-CD45RO, anti-human-PD-1, and anti-human-FoxP3, multiplex cytokine analyses including IFN-gamma and TGF-beta, and multiplex-immunohistochemistry. We expect to observe the synergistic inhibitory effect of LXR-623 and anti-PD1-Abs against chordomas through PD-L1 downregulation and reduction in immunosuppressive MDSC levels mediated by LXR-623. We plan to sacrifice the last animal group on August 24th. Due to the lengthy nature of the experiment (humanization and treatment take 13–14 weeks), the data are not fully available at the time of submission but will be available by the late-breaking deadline.

  • Open Access

    Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system

    by Russell Maxwell, Andrew S. Luksik, Tomas Garzon-Muvdi, Alice L. Hung, Eileen S. Kim, Adela Wu, Yuanxuan Xia, Zineb Belcaid, Noah Gorelick, John Choi, et al.

    Immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) is emerging as an important treatment strategy in a growing list of cancers, yet its clinical benefits are limited to a subset of patients. Further investigation of tumor-intrinsic predictors of response and how extrinsic factors, such as iatrogenic immunosuppression caused by conventional therapies, impact the efficacy of anti-PD-1 therapy are paramount. Given the widespread use of corticosteroids in cancer management and their immunosuppressive nature, this study sought to determine how corticosteroids influence anti-PD-1 responses and whether their effects were dependent on tumor location within the periphery versus central nervous system (CNS), which may have a more limiting immune environment. In well-established anti-PD-1-responsive murine tumor models, corticosteroid therapy resulted in systemic immune effects, including severe and persistent reductions in peripheral CD4+ and CD8 + T cells. Corticosteroid treatment was found to diminish the efficacy of anti-PD-1 therapy in mice bearing peripheral tumors with responses correlating with peripheral CD8/Treg ratio changes. In contrast, in mice bearing intracranial tumors, corticosteroids did not abrogate the benefits conferred by anti-PD-1 therapy. Despite systemic immune changes, anti-PD-1-mediated antitumor immune responses remained intact during corticosteroid treatment in mice bearing intracranial tumors. These findings suggest that anti-PD-1 responses may be differentially impacted by concomitant corticosteroid use depending on tumor location within or outside the CNS. As an immune-specialized site, the CNS may potentially play a protective role against the immunosuppressive effects of corticosteroids, thus sustaining antitumor immune responses mediated by PD-1 blockade.